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Abstract
Background: The platelet P2Y12 receptor plays a key role in platelet activation. The H2 haplotype
of the P2Y12 receptor gene (P2RY12) has been found to be associated with maximal aggregation
response to adenosine diphosphate (ADP) and with increased risk for peripheral arterial disease.
No data are available on its association with coronary artery disease (CAD).
Methods : The H2 haplotype of the P2RY12 was determined in 1378 unrelated patients of both
sexes selected according to the presence of significant coronary artery disease (CAD group) or
having normal coronary angiogram at cardiac catheterization (CAD-free group). Significant
coronary artery disease was angiographically determined, and was defined as a greater than 50%
visually estimated luminal diameter stenosis in at least one major epicardial coronary artery.
Results: In the studied population 71.9% had CAD (n = 991) and 28.1% had normal coronary
angiogram (n = 387). H2 haplotype carriers were more frequent in the CAD group (p = 0.03, OR
= 1.36, 95%CI = 1.02–1.82). The H2 haplotype was significantly associated with CAD in non-
smokers (p = 0.007, OR = 1.83 95%CI = 1.17–2.87), but not in smokers. The association remained
significant after adjustment for other covariates (age, triglycerides, HDL, hypertension, diabetes) by
multivariate logistic regression (p = 0.004, OR = 2.32 95%CI = 1.30–4.15).
Conclusion: Gene sequence variations of the P2Y12 receptor gene are associated with the
presence of significant CAD, particularly in non-smoking individuals.
Background
Platelets play a key role in the pathophysiology of athero-
sclerotic disease and its complications [1,2]. Importantly,
platelet function varies considerably among individuals
and subjects with enhanced platelet reactivity have
increased atherothrombotic risk [3]. The adenosine
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platelet activation [4]. The relevance of this receptor is
demonstrated by the clinical benefit obtained in patients
when it is blocked by the P2Y12 receptor antagonist clopi-
dogrel [5,6]. Recently, Fontana et al. identified two func-
tional haplotypes designated as H1 and H2, tagged by 4
single nucleotide polymorphisms (SNPs) in absolute
linkage disequilibrium (i-C139T, i-T744C, i-ins801A,
G52T). Importantly, the minor haplotype (H2) was found
to be associated with enhanced platelet reactivity suggest-
ing a role for gene sequence variations of the P2Y12 recep-
tor in atherothrombotic processes [7]. Notably, the H2
haplotype has also shown to be associated with peripheral
arterial disease [8]. However, its association with coronary
atherosclerotic disease has still been poorly explored. To
investigate whether this H2 haplotype of the P2Y12 recep-
tor gene may be associated with coronary artery disease,
we studied the distribution of the i-T744C SNP in 1378
unrelated patients, selected according to the presence of
significant coronary artery disease (N = 991) or of normal
coronary angiogram at cardiac catheterization (N = 387).
Methods
Study population
A total of 1945 consecutive subjects undergoing cardiac
catheterization at the University Hospital of Verona were
recruited from 1996 to 2005. All subjects were unrelated
and of Italian origin from the same geographic area in
North-Eastern Italy. Further details on the enrolling crite-
ria have been described elsewhere [9,10].
In the present study we used data from 1378 patients, for
whom P2RY12 genotypes were available, selected accord-
ing to the presence of significant coronary artery disease
(CAD group) or having normal coronary angiogram at
cardiac catheterization (CAD-free group). Significant cor-
onary artery disease was angiographically determined
after the first manifestation of symptoms of ischemic
heart disease and was defined as a greater than 50% visu-
ally estimated luminal diameter stenosis in at least one
major epicardial coronary artery. Most of CAD patients
were candidate to coronary artery bypass grafting (CABG).
Since the primary aim of our selection was to provide an
objective and clear-cut definition of the atherosclerotic
phenotype, subjects with non significant coronary steno-
sis (< 50%) were not included in the study. Most of the
patients have not been treated with antiplatelet drugs
before the recruitment. After CABG, 90% of patients have
been treated with aspirin, about 9% with ticlopidina and
1% with indobuphen. No patients had therapy with clopi-
dogrel. Controls (CAD-free group), mainly examined for
valvular heart disease, were enrolled providing that they
had not only a normal coronary angiogram at cardiac
catheterization, but also neither history nor clinical or
instrumental evidence of atherosclerosis in vascular dis-
tricts other than the coronary bed. The angiograms were
assessed by two cardiologists unaware that the patients
were to be included in the study.
All individuals gave a written consent before entering the
study, which was approved by the Ethical Committee of
the University Hospital of Verona.
Genotyping
Individuals were genotyped for the i-T744C SNP (NCBI
refSEQ: rs2046934) of the P2Y12 receptor gene (P2RY12)
in order to tag the H1(744T) and H2 (744C) haplotypes
[7]. Genomic DNA was prepared from whole blood sam-
ples by standard procedures. Genotyping was performed
with LightCycler® 2.0 System (Roche Applied Science,
Mannheim, Germany) by Real-Time PCR assay and anal-
ysis of samples melting curves. Primers and Fluorescence
Resonance Energy Transfer (FRET) probes were designed
using LightCycler® Probe Design Software 2.0 (Roche
Applied Science, Mannheim, Germany), as shown in
Table 1.
Genotyping assay consisted of four programs, including
pre-incubation (95°C × 10 min), amplification (95°C ×
10 sec – 58°C × 10 sec – 72°C × 12 sec, 40 cycles, ramp:
20°C/sec), melting-curve analysis (50°C to 75°C, ramp:
0.2°C/sec) and cooling (20°C × 10 sec). Primers and
probes concentrations were determined according to
standard protocols. Since the i-T744C SNP of the P2RY12
gene is a component in total linkage disequilibrium with
other 3 SNPs used to tag the H1/H2 haplotype, subjects
carriers of the variant C allele are also referred to as H2
haplotype carriers.
In addition to observing the association of a specific gen-
otype presentation (H1/H1; H1/H2; H2/H2) on CAD,
considering also the low number of H2/H2 subjects, we
compare subjects homozygous for the wild-type allele
with subjects carrying the minor allele, according to a
dominant model. Therefore, patients were considered as
carriers (H1/H2 and H2/H2) and non carriers (H1/H1) of
the H2 haplotype.
Statistical analysis
All the statistical analyses were performed with the R sta-
tistical package [11]. Our calculations, based on the
marker allele frequency in CEU population derived from
the HapMap Project [12], indicate that our sample size is
adequate to detect a SNP or haplotype with a modest
effect (significance level = 0.05, power = 80%, OR ≥ 1.42).
Distribution of continuous variables in groups was
expressed as mean ± standard deviation. Quantitative data
were analysed using Student's t-test. Qualitative data were
analysed with a χ2 test. Genotype frequencies of differentPage 2 of 6
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tables. Significant difference in genotype distribution
were estimated by χ2test. Hardy-Weinberg equilibrium
was tested in patients with and without CAD by χ2 test
with Yates' correction for continuity. Risk adjustment was
performed in a multiple forward stepwise logistic regres-
sion analysis. Variables included in this model were age,
sex, body mass index, glucose, total cholesterol, HDL,
LDL, triglycerides, diabetes, smoking habitus, hyperten-
sion status.
Results
All 1378 subjects were successfully genotyped; of these
991 subjects had significant CAD. Demographics of the
study population are described in Table 2. As expected,
cardiovascular risk factors were more frequently found in
subjects with angiographic evidence of significant CAD.
In the overall patient population, the allele and genotype
distribution were as follows: C allele frequency, 12.8%;
H1/H1, 1046 (75.9%); H1/H2, 310 (22.5%); H2/H2, 22
(1.6%). Genotype distribution of the i-T744C polymor-
phism tagging the H1/H2 haplotype in the study popula-
tion in the CAD and CAD-free groups is shown in Table 3.
C allele frequency was 13.47% and 11.24% in CAD and
CAD-free subjects, respectively (p > 0.05). Genotype dis-
tribution was in Hardy-Weinberg equilibrium. A signifi-
cant difference was observed in the distribution of the
three genotypes between the two groups (p = 0.017). Car-
riers of the minor haplotype (H1/H2 + H2/H2) were more
frequent in patients with significant CAD (p = 0.03, OR =
1.36, 95%CI = 1.02–1.82). Such association was close to
significance in males (p = 0.05), but not in females, even
if in the two subgroups the H2 haplotype carriers tended
to be more frequent among CAD patients (data not
shown). The association remained close to significance
threshold after adjustment for other covariates (age, sex,
BMI, triglycerides, HDL, LDL, hypertension, smoking and
diabetes) by multivariate logistic regression (p = 0.05, OR
= 1.42, 95%CI = 1.18–1.71).
The hypothesis of interaction between the P2RY12 gene
and variables involved in atherosclerotic risk was then
evaluated. Interactions with a p-value ≤ 0.1 were further
evaluated through stratification of the studied population
for the interacting factor. Only smoking met this criterion
(p for interaction = 0.026), consequently genotype distri-
bution of the i-T744C polymorphism of the P2RY12 gene
was evaluated in smokers and non-smokers as shown in
Table 4. Non-smokers carrying the minor haplotype H2
were highly associated with significant CAD (p = 0.007,
OR = 1.83, 95%CI = 1.17–2.87). The association
remained significant after adjustment for other covariates
(age, sex, BMI, triglycerides, HDL, LDL, hypertension and
diabetes) by multiple logistic regression (p = 0.004, OR =
2.32, 95%CI = 1.30–4.15) and after adjustment for multi-
ple tests (p = 0.014). No other significant interaction was
found between the H2 haplotype of the P2RY12 gene and
other variables.
Discussion
The present report is the first to demonstrate an associa-
tion between the minor H2 haplotype of the P2RY12 gene
and presence of significant coronary artery disease. Thus
the finding of the present study further extends our
knowledge on the implications of gene sequence varia-
tions of this receptor, a key player in platelet function, on
atherothrombosis. In fact, to date this polymorphism has
shown to be associated with peripheral arterial disease
[8], while its association with coronary artery disease has
been poorly explored.
One prior report has assessed the association between this
haplotype and long term complications of coronary artery
disease (cardiac death, myocardial infarction and refrac-
tory angina requiring revascularization) but failed to find
any association [13]. It may be argued that this study had
a limited statistical power to detect the implications of
this polymorphism given the relatively small sample size
Table 2: Demographics of the study population in the CAD and 
CAD-free groups
CAD = 991 CAD-free = 387 p-value
Age (yr) 61.38 ± 9.81 58.78 ± 12.3 < 0.001
Males 79.8% 65% < 0.001
Body Mass Index (kg/m2) 26.74 ± 3.54 25.35 ± 3.45 < 0.001
Glucose (mmol/l) 5.84 ± 1.6 5.51 ± 0.93 < 0.001
Total cholesterol (mmol/l) 5.56 ± 1.17 5.44 ± 1.11 n.s.
HDL (mmol/l) 1.19 ± 0.31 1.42 ± 0.42 < 0.001
LDL (mmol/l) 3.73 ± 0.99 3.52 ± 0.93 < 0.01
Triglycerides (mmol/dl) 1.92 ± 1.05 1.48 ± 0.68 < 0.001
Diabetes Mellitus 20.1% 7.2% < 0.001
Hypertension 65.4% 40.4% < 0.001
Current smokers 65.6% 41.1% < 0.001
Table 1: Primers and probes used to genotype the i-T744C 
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evaluated.
The P2RY12 gene is located in the P2 receptor gene cluster
on chromosome 3q24-q25. The mechanisms through
which these gene sequence variations might lead to an
increased atherothrombotic risk are still not well estab-
lished. Fontana et al. showed that the H2 haplotype of the
P2RY12 gene is associated with increased platelet function
in non-medicated healthy volunteers [7]. Notably, plate-
let activation plays a leading role in the initiation and
development of atherosclerosis as well as in its complica-
tions. The seminal findings from Fontana et al have led to
the hypothesis that this genetic polymorphism may be
responsible for modulation of individual responsiveness
to antiplatelet agents.
On the other hand, platelet function studies performed by
the same authors as well as other executed in medically
treated patients with clinical manifestations of atheroscle-
rotic disease did not show any modulating effects of this
genetic polymorphism on individual responsiveness to
aspirin or clopidogrel [14-17]. Therefore, despite the key
role of P2RY12 receptor on inducing platelet activation, it
is likely that genetic polymorphisms of other targets may
be more important in modulating aspirin and clopidogrel
effects[18]. Moreover, Hetherington et al [19] reported no
significant effect of P2RY12 SNPs, including the i-T744C
one, on platelet response to ADP in subjects without his-
tory of CAD, and an association of a common variant in
P2Y1 gene with platelet reactivity.
Atherosclerosis is a multifactorial disease and involves
both environmental and genetic factors. Therefore, the
low penetrance of a single functional polymorphism may
not always lead to a clinical phenotype as this may be
obscured by environmental factors. This may explain why
the H2 haplotype of P2RY12 gene had its strongest associ-
ation with CAD in non-smoking individuals. Notably,
platelets isolated from smokers exhibit increased reactiv-
ity as well as spontaneous aggregation [20]. Moreover,
nicotine upregulates the expression of P2Y12 receptors on
vascular cells and megakaryoblasts, and smokers exhibit
higher P2Y12 expression [21]. Therefore, the presence of
genetic determinants leading to increased platelet func-
tion profiles may be masked by cigarette smoking. Nota-
bly, the association between the H2 haplotype and CAD
in non-smokers remained significant even after adjust-
ment for other covariates (age, sex, BMI, triglycerides,
HDL, LDL, hypertension, smoking and diabetes) by mul-
tivariate logistic regression, suggesting that the P2RY12
gene is an independent risk factor for coronary artery dis-
ease in these subjects.
The complex interplay between genetic and environmen-
tal factors on the development of atherosclerotic disease
explains why large study populations are required to
define if a particular functional polymorphism may have
Table 4: Genotype frequency of the i-T744C SNP of the P2RY12 gene according to smoking habit
Smokers (n = 809) Non-smokers (n = 503)
CAD CAD-free OR (CI 95%) 
p-value *
CAD CAD-free OR (CI 95%) 
p-value *
T/T 490 (75.4%) 121 (76.1%) 221 (72.5%) 164 (82.8%)
T/C 150 (23%) 35 (22%) 1.04
(0.69–1.56)
81 (26.5%) 28 (14.2%) 1.83
C/C 10 (1.6%) 3 (1.9%) p = 0.85 3 (1%) 6 (3%) (1.17–2.87)
TC+CC 160 (24.6%) 38 (23.9%) 84 (27.5%) 34 (17.2%) p = 0.007
*T/C and C/C genotypes (H1/H2 and H2/H2 haplotypes, respectively) are pooled in the CAD and in the CAD-free group for p-value and OR 
calculation.
Table 3: Genotype frequency of the i-T744C SNP of the P2RY12 gene in patients with and without significant coronary artery disease
CAD CAD-free OR (CI 95%) p-value*
T/T 737 (74.37%) 309 (79.84%)
T/C 241 (24.32%) 69 (17.83%) 1.36
C/C 13 (1.31%) 9 (2.33%) 1.02–1.82
TC+CC 254 (25.63%) 78 (20.16%) 0.03
*T/C and C/C genotypes (H1/H2 and H2/H2 haplotypes, respectively) are pooled in the CAD and in the CAD-free group for p-value and OR 
calculation.Page 4 of 6
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activation), but also on clinical phenotypes (e.g. athero-
sclerosis). In the present study, as expected, conventional
cardiovascular risk factors were more common in patients
with CAD. However, it was also demonstrated that the H2
haplotype was more frequently present in patients with
CAD. This observation is in keeping with the concept that
in multifactorial diseases, genetic polymorphisms influ-
ence the risk of disease by determining a different individ-
ual susceptibility to environmental risk factors rather than
being the cause of the disease process itself.
The primary end-point of the present work was to investi-
gate the association between CAD and the i-T744C SNP of
the P2RY12 gene through a case-control study in unre-
lated individuals. Certainly the study has some limita-
tions, such as the relatively low number of controls and
no available data on platelet aggregation. On the other
hand, the sample size of our study-population was ade-
quate to detect a mild effect on phenotype by this genetic
variant. A strength of this work was the clear-cut defini-
tion of CAD phenotype on the basis of coronary angiogra-
phy, which is of pivotal importance in the analysis of
genotype-phenotype correlation. Male and female sub-
groups showed H2 haplotype carriers more frequently in
CAD patients, and it is likely that these observation did
not reach the statistical significance due to the small size
of each group after stratification.
Conclusion
This study supports the previously reported association of
P2RY12 gene with atherosclerosis, giving for the first time
genetic association data for the presence of significant cor-
onary artery disease, particularly in non-smoking individ-
uals. Nonetheless, this correlation remains still
controversial [7,19] and further studies, possibly with
prospective design, are needed to confirm these data.
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